Authors:
Xu, YC
Johnson, KW
Phebus, LA
Cohen, M
Nelson, DL
Schenck, K
Walker, CD
Fritz, JE
Kaldor, SW
LeTourneau, ME
Murff, RE
Zgombick, JM
Calligaro, DO
Audia, JE
Schaus, JM
Citation: Yc. Xu et al., N-[3-(2-dimethylaminoethyl)-2-methyl-1H-indol-5-yl]-4-fluorobenzamide: A potent, selective, and orally active 5-HT1F receptor agonist potentially useful for migraine therapy, J MED CHEM, 44(24), 2001, pp. 4031-4034
Authors:
Rasmussen, K
Calligaro, DO
Czachura, JF
Dreshfield-Ahmad, LJ
Evans, DC
Hemrick-Luecke, SK
Kallman, MJ
Kendrick, WT
Leander, JD
Nelson, DL
Overshiner, CD
Wainscott, DB
Wolff, MC
Wong, DT
Branchek, TA
Zgombick, JM
Xu, YC
Citation: K. Rasmussen et al., The novel 5-hydroxytryptamine(1A) antagonist LY426965: effects on nicotinewithdrawal and interactions with fluoxetine, J PHARM EXP, 294(2), 2000, pp. 688-700
Authors:
Chen, JJ
Vasko, MR
Wu, XP
Staeva, TP
Baez, M
Zgombick, JM
Nelson, DL
Citation: Jj. Chen et al., Multiple subtypes of serotonin receptors are expressed in rat sensory neurons in culture, J PHARM EXP, 287(3), 1998, pp. 1119-1127